Objective To investigate the clinical efficacy of thymus pentapeptide combined with thymopentin in treatment of stable stage of grade Ⅲ and Ⅳ chronic obstructive pulmonary disease.Methods Patients(150 cases)with stable stage of grade Ⅲ and Ⅳchronic obstructive pulmonary disease in the Sixth Affiliated Hospital of Xinjiang Medical University from June 2021 to June 2023 were randomly divided into control(75 cases)and treatment(75 cases)group.Patients in the control group were inhaled with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol,2 puffs/time,twice daily.Patients in the treatment group were subcutaneous injection administered with Thymopentin for injection,10 mg/time,twice weekly.Patients in two groups were treated for 3 months.After treatment,the clinical evaluations were evaluated,the levels of lung function indexes FEV1/FVC,FEV1%and RV/TLC,the levels of immune function indexes CD3+,CD4+and CD4+/CD8+,the levels of airway mucus hypersecretion indexes dry/wet density of sputum and MUC5AC,and the prognosis in two groups before and after treatment were compared.Results After treatment,the total effective rate in the treatment group was significantly higher than that in the control group(94.67%vs 82.67%,P<0.05).After treatment,the levels of FEV1/FVC,FEV1%,CD3+,CD4+,and CD4+/CD8+in two groups were significantly higher than before treatment,while the levels of RV/TLC,dry/wet sputum specific gravity,and MUC5AC were significantly lower(P<0.05).After treatment,these indicators of lung function,immune function and airway mucus hypersecretion in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the number of COPD exacerbations and the re-hospitalization rate in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Thymopentin combined with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol can regulate immune function,relieve airway mucus hypersecretion,improve lung function,improve clinical efficacy,and further improve prognosis in stable COPD patients with grade Ⅲ and Ⅳ.
Thymopentin for injectionBudesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosolchronic obstructive pulmonary diseaselung functionimmune functionairway mucus hypersecretion
万方数据
